Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger.

Amza A, Kadri B, Nassirou B, Yu SN, Stoller NE, Bhosai SJ, Zhou Z, McCulloch CE, West SK, Bailey RL, Keenan JD, Lietman TM, Gaynor BD.

PLoS Negl Trop Dis. 2013;7(1):e1983. doi: 10.1371/journal.pntd.0001983. Epub 2013 Jan 10.

2.

Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.

Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, Chin S, West SK, Bailey RL, Mabey DC, Keenan JD, Porco TC, Lietman TM, Gaynor BD; PRET Partnership.

PLoS Negl Trop Dis. 2012;6(4):e1586. doi: 10.1371/journal.pntd.0001586. Epub 2012 Apr 24.

3.

Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.

Burton MJ, Holland MJ, Makalo P, Aryee EA, Sillah A, Cohuet S, Natividad A, Alexander ND, Mabey DC, Bailey RL.

PLoS Negl Trop Dis. 2010 Oct 5;4(10). pii: e835. doi: 10.1371/journal.pntd.0000835.

4.

Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification.

Yang JL, Hong KC, Schachter J, Moncada J, Lekew T, House JI, Zhou Z, Neuwelt MD, Rutar T, Halfpenny C, Shah N, Whitcher JP, Lietman TM.

Invest Ophthalmol Vis Sci. 2009 Jan;50(1):90-4. doi: 10.1167/iovs.08-2247. Epub 2008 Aug 8.

PMID:
18689701
5.

Risk factors for ocular chlamydia after three mass azithromycin distributions.

Ayele B, Gebre T, Moncada J, House JI, Stoller NE, Zhou Z, Porco TC, Gaynor BD, Emerson PM, Schachter J, Keenan JD.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1441. doi: 10.1371/journal.pntd.0001441. Epub 2011 Dec 13.

6.

Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.

Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, Zhou Z, Moncada J, Rogér A, Keenan J, Gaynor BD, Schachter J, Lietman TM.

Ophthalmology. 2009 Nov;116(11):2047-50. doi: 10.1016/j.ophtha.2009.04.041. Epub 2009 Sep 10.

PMID:
19744717
7.

Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.

Edwards T, Harding-Esch EM, Hailu G, Andreason A, Mabey DC, Todd J, Cumberland P.

Trop Med Int Health. 2008 Apr;13(4):556-65. doi: 10.1111/j.1365-3156.2008.02034.x. Epub 2008 Feb 14.

8.

How much is not enough? A community randomized trial of a Water and Health Education programme for Trachoma and Ocular C. trachomatis infection in Niger.

Abdou A, Munoz BE, Nassirou B, Kadri B, Moussa F, Baarè I, Riverson J, Opong E, West SK.

Trop Med Int Health. 2010 Jan;15(1):98-104. doi: 10.1111/j.1365-3156.2009.02429.x.

10.

Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger.

Abdou A, Nassirou B, Kadri B, Moussa F, Munoz BE, Opong E, West SK.

Br J Ophthalmol. 2007 Jan;91(1):13-7. Epub 2006 Aug 9.

11.

Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program.

Pant BP, Bhatta RC, Chaudhary JS, Awasthi S, Mishra S, Sharma S, Cuddapah PA, Gwyn SE, Stoller NE, Martin DL, Keenan JD, Lietman TM, Gaynor BD.

PLoS Negl Trop Dis. 2016 Feb 12;10(2):e0004462. doi: 10.1371/journal.pntd.0004462. eCollection 2016 Feb.

12.

The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.

Lee JS, Muñoz BE, Mkocha H, Gaydos CA, Quinn TC, West SK.

PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2761. doi: 10.1371/journal.pntd.0002761. eCollection 2014 Apr.

13.

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.

West SK, Munoz B, Mkocha H, Gaydos C, Quinn T.

Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1492-7.

PMID:
17389476
14.

Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma.

Yang JL, Schachter J, Moncada J, Habte D, Zerihun M, House JI, Zhou Z, Hong KC, Maxey K, Gaynor BD, Lietman TM.

Br J Ophthalmol. 2007 Mar;91(3):293-5. Epub 2006 Oct 18.

15.

Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Keenan JD, See CW, Moncada J, Ayele B, Gebre T, Stoller NE, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Schachter J, Lietman TM.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):235-40. doi: 10.1167/iovs.11-8493.

16.

Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.

Cajas-Monson LC, Mkocha H, Muñoz B, Quinn TC, Gaydos CA, West SK.

PLoS Negl Trop Dis. 2011 Mar 15;5(3):e978. doi: 10.1371/journal.pntd.0000978.

17.

Strategies for control of trachoma: observational study with quantitative PCR.

Solomon AW, Holland MJ, Burton MJ, West SK, Alexander ND, Aguirre A, Massae PA, Mkocha H, Muñoz B, Johnson GJ, Peeling RW, Bailey RL, Foster A, Mabey DC.

Lancet. 2003 Jul 19;362(9379):198-204.

PMID:
12885481
18.

Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.

West SK, Munoz B, Mkocha H, Gaydos CA, Quinn TC.

J Infect Dis. 2011 Jul 15;204(2):268-73. doi: 10.1093/infdis/jir257.

19.

Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.

West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Foster A, Bailey RL, Mabey DC.

Lancet. 2005 Oct 8;366(9493):1296-300.

PMID:
16214600
20.

Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.

Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, Quinn T, West SK.

JAMA Ophthalmol. 2013 Apr;131(4):431-6. doi: 10.1001/jamaophthalmol.2013.2356.

Supplemental Content

Support Center